Literature DB >> 8340761

Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation.

M H Tao1, R I Smith, S L Morrison.   

Abstract

Although very similar in sequence, the four subclasses of human immunoglobulin G (IgG) differ markedly in their ability to activate complement. Glu318-Lys320-Lys322 has been identified as a key binding motif for the first component of complement, C1q, and is present in all isotypes of Ig capable of activating complement. This motif, however, is present in all subclasses of human IgG, including those that show little (IgG2) or even no (IgG4) complement activity. Using point mutants of chimeric antibodies, we have identified specific residues responsible for the differing ability of the IgG subclasses to fix complement. In particular, we show that Ser at position 331 in gamma 4 is critical for determining the inability of that isotype to bind C1q and activate complement. Additionally, we provide further evidence that levels of C1q binding do not necessarily correlate with levels of complement activity, and that C1q binding alone is not sufficient for complement activation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8340761      PMCID: PMC2191116          DOI: 10.1084/jem.178.2.661

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  26 in total

1.  Complement activation by IgM: evidence for the importance of the third constant domain of the mu heavy chain.

Authors:  M J Shulman; C Collins; N Pennell; N Hozumi
Journal:  Eur J Immunol       Date:  1987-04       Impact factor: 5.532

2.  Localization of the binding site for the human high-affinity Fc receptor on IgG.

Authors:  A R Duncan; J M Woof; L J Partridge; D R Burton; G Winter
Journal:  Nature       Date:  1988-04-07       Impact factor: 49.962

Review 3.  Immunoglobulin G: functional sites.

Authors:  D R Burton
Journal:  Mol Immunol       Date:  1985-03       Impact factor: 4.407

4.  Correlation between segmental flexibility and effector function of antibodies.

Authors:  V T Oi; T M Vuong; R Hardy; J Reidler; J Dangle; L A Herzenberg; L Stryer
Journal:  Nature       Date:  1984 Jan 12-18       Impact factor: 49.962

5.  Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region.

Authors:  M Klein; N Haeffner-Cavaillon; D E Isenman; C Rivat; M A Navia; D R Davies; K J Dorrington
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

6.  Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor.

Authors:  R J Leatherbarrow; T W Rademacher; R A Dwek; J M Woof; A Clark; D R Burton; N Richardson; A Feinstein
Journal:  Mol Immunol       Date:  1985-04       Impact factor: 4.407

7.  Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution.

Authors:  J Deisenhofer
Journal:  Biochemistry       Date:  1981-04-28       Impact factor: 3.162

8.  Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template.

Authors:  M J Zoller; M Smith
Journal:  DNA       Date:  1984-12

9.  Preparation and biologic characterization of fragments containing dimeric and monomeric C gamma 2 domain of rabbit IgG.

Authors:  S Utsumi; M Okada; K Udaka; T Amano
Journal:  Mol Immunol       Date:  1985-07       Impact factor: 4.407

10.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

Authors:  M Brüggemann; G T Williams; C I Bindon; M R Clark; M R Walker; R Jefferis; H Waldmann; M S Neuberger
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  82 in total

1.  Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.

Authors:  Jing Qi Feng; Krystyna Mozdzanowska; Walter Gerhard
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Development of a specific system for targeting protein to metallophilic macrophages.

Authors:  Philip R Taylor; Susanne Zamze; Richard J Stillion; Simon Y C Wong; Siamon Gordon; Luisa Martinez-Pomares
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-05       Impact factor: 11.205

3.  From Rhesus macaque to human: structural evolutionary pathways for immunoglobulin G subclasses.

Authors:  William David Tolbert; Ganesh Prasad Subedi; Neelakshi Gohain; George Kenneth Lewis; Kashyap Rajesh Patel; Adam Wesley Barb; Marzena Pazgier
Journal:  MAbs       Date:  2019-04-02       Impact factor: 5.857

Review 4.  Regulation of antibody effector functions through IgG Fc N-glycosylation.

Authors:  Isaak Quast; Benjamin Peschke; Jan D Lünemann
Journal:  Cell Mol Life Sci       Date:  2016-09-17       Impact factor: 9.261

5.  The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.

Authors:  Lucy E Rayner; Gar Kay Hui; Jayesh Gor; Richard K Heenan; Paul A Dalby; Stephen J Perkins
Journal:  J Biol Chem       Date:  2015-02-06       Impact factor: 5.157

6.  Proliferative glomerulonephritis with monoclonal IgG2κ deposit successfully treated with steroids: a case report and review of the literature.

Authors:  Ryuji Ohashi; Yukinao Sakai; Tomoyuki Otsuka; Dai Ohno; Yukinari Masuda; Tsuneo Murasawa; Naoki Sato; Akira Shimizu
Journal:  CEN Case Rep       Date:  2013-02-26

Review 7.  Heavy chain deposition disease: an overview.

Authors:  Yuji Oe; Jun Soma; Hiroshi Sato; Sadayoshi Ito
Journal:  Clin Exp Nephrol       Date:  2013-05-08       Impact factor: 2.801

8.  Transferrin-antibody fusion proteins are effective in brain targeting.

Authors:  S U Shin; P Friden; M Moran; T Olson; Y S Kang; W M Pardridge; S L Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  Influence of IgG Subclass on Human Antimannan Antibody-Mediated Resistance to Hematogenously Disseminated Candidiasis in Mice.

Authors:  Casey T Nishiya; Gayle M Boxx; Kerry Robison; Carol Itatani; Thomas R Kozel; Mason X Zhang
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

10.  Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Authors:  Kham R Trinh; Alex Vasuthasawat; Kristopher K Steward; Reiko E Yamada; John M Timmerman; Sherie L Morrison
Journal:  J Immunother       Date:  2013-06       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.